<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103826</url>
  </required_header>
  <id_info>
    <org_study_id>SHR6390-SHR1020-I-101-BC</org_study_id>
    <nct_id>NCT05103826</nct_id>
  </id_info>
  <brief_title>A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer</brief_title>
  <official_title>A Phase I Study to Evaluate Safety 、Tolerability 、 Pharmacokinetics and Efficacy of SHR6390 in Combination With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to assess the safety 、tolerability 、 pharmacokinetics and&#xD;
      efficacy of SHR6390 combined with famitinib in the treatment of ER + / HER2- advanced breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 25, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Safety Lead-in) dose limited toxicity (DLT) of SHR6390+famitinib in the first cycle</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Safety Lead-in) Recommended Phase II Dose (RP2D) of SHR6390+famitinib</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AEs+SAEs</measure>
    <time_frame>up to 24 months</time_frame>
    <description>from the first drug administration to within 30 days for the last treatment dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of SHR6390+famitinib: Cmax</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of SHR6390+famitinib: Tmax</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of SHR6390+famitinib: t1/2</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of SHR6390+famitinib: AUC</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of SHR6390+famitinib: CL/F</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of SHR6390+famitinib: Vz/F</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of SHR6390+famitinib: Rac</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Number of responders Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) for target lesions assessed by CT or MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Complete response + Partial response + Stable disease (CR+PR+SD) based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Time from documentation of tumor response to disease progression assessed among patients who had an objective response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>ER+ / HER2- Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SHR6390+famitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SHR6390 in combination with famitinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390、Famitinib</intervention_name>
    <description>SHR6390, oral;Famitinib, oral.</description>
    <arm_group_label>SHR6390+famitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female subjects aged 18 to 75 years old；&#xD;
&#xD;
          2. ECOG performance status 0-1;&#xD;
&#xD;
          3. Life expectancy is not less than 12 weeks;&#xD;
&#xD;
          4. Histological or cytological confirmation of ER+/HER2- recurrent/metastatic breast&#xD;
             cancer;&#xD;
&#xD;
          5. Participants with measurable disease must have at least one &quot;target lesion&quot; to be used&#xD;
             to assess response on this protocol as defined by RECIST1.1;&#xD;
&#xD;
          6. Adequate function of major organs;&#xD;
&#xD;
          7. Voluntary participation in the study, signed informed consent, good compliance and&#xD;
             willingness to cooperate with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of HER2 positive disease;&#xD;
&#xD;
          2. Participants who previously received SHR6390 or VEGFR inhibitors;&#xD;
&#xD;
          3. Allergy to study drug or its components;&#xD;
&#xD;
          4. Participated in other drug clinical trials within 4 weeks before the first dose;&#xD;
&#xD;
          5. Other malignancies within 3 years, except cured non-melanoma skin cancer , skin basal&#xD;
             cell carcinoma and squamous-cell carcinoma or carcinoma in situ of the cervix;&#xD;
&#xD;
          6. Clinically significant cardiovascular and cerebrovascular diseases,including but not&#xD;
             limited to severe acute myocardial infarction within 6 months before enrollment,&#xD;
             unstable or severe angina, Congestive heart failure (New York heart association (NYHA)&#xD;
             class &gt; 2), or ventricular arrhythmia which need medical intervention；&#xD;
&#xD;
          7. Tumor has invaded important blood vessels or the tumor is likely to invade important&#xD;
             blood vessels and cause fatal hemorrhage during treatment;&#xD;
&#xD;
          8. Urine routine test indicates urine protein ≥(++), or 24-hour urine protein &gt;1.0g;&#xD;
&#xD;
          9. Active HBV/HCV/HIV infection;&#xD;
&#xD;
         10. The investigators determined that other conditions were inappropriate for&#xD;
             participation in this clinical trial；&#xD;
&#xD;
         11. Pregnant or breast-feeding women;&#xD;
&#xD;
         12. Central nervous system (CNS) invasion.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoyu Zhu, M.D</last_name>
    <phone>+86 13774383638</phone>
    <email>xiaoyu.zhu@hengrui.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

